Logo image of EXAI

EXSCIENTIA PLC (EXAI) Stock Fundamental Analysis

USA - NASDAQ:EXAI - US30223G1022 - ADR

4.84 USD
+0.15 (+3.2%)
Last: 11/19/2024, 8:18:05 PM
4.85 USD
+0.01 (+0.21%)
After Hours: 11/19/2024, 8:18:05 PM
Fundamental Rating

2

Overall EXAI gets a fundamental rating of 2 out of 10. We evaluated EXAI against 538 industry peers in the Biotechnology industry. EXAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EXAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EXAI had negative earnings in the past year.
In the past year EXAI has reported a negative cash flow from operations.
EXAI had negative earnings in each of the past 5 years.
In the past 5 years EXAI reported 4 times negative operating cash flow.
EXAI Yearly Net Income VS EBIT VS OCF VS FCFEXAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of EXAI (-25.37%) is better than 73.06% of its industry peers.
With a decent Return On Equity value of -36.43%, EXAI is doing good in the industry, outperforming 75.53% of the companies in the same industry.
Industry RankSector Rank
ROA -25.37%
ROE -36.43%
ROIC N/A
ROA(3y)-18.33%
ROA(5y)-19.31%
ROE(3y)-25.04%
ROE(5y)-27.69%
ROIC(3y)N/A
ROIC(5y)N/A
EXAI Yearly ROA, ROE, ROICEXAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EXAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EXAI Yearly Profit, Operating, Gross MarginsEXAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

4

2. Health

2.1 Basic Checks

EXAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EXAI has been increased compared to 1 year ago.
The debt/assets ratio for EXAI is higher compared to a year ago.
EXAI Yearly Shares OutstandingEXAI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
EXAI Yearly Total Debt VS Total AssetsEXAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.78, we must say that EXAI is in the distress zone and has some risk of bankruptcy.
EXAI has a better Altman-Z score (1.78) than 69.19% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that EXAI is not too dependend on debt financing.
EXAI's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. EXAI is outperformed by 60.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.78
ROIC/WACCN/A
WACC8.54%
EXAI Yearly LT Debt VS Equity VS FCFEXAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 6.22 indicates that EXAI has no problem at all paying its short term obligations.
EXAI has a better Current ratio (6.22) than 62.68% of its industry peers.
EXAI has a Quick Ratio of 6.22. This indicates that EXAI is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.22, EXAI is doing good in the industry, outperforming 63.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.22
Quick Ratio 6.22
EXAI Yearly Current Assets VS Current LiabilitesEXAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.11% over the past year.
EXAI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.64%.
The Revenue has been growing by 17.43% on average over the past years. This is quite good.
EPS 1Y (TTM)5.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.14%
Revenue 1Y (TTM)-19.64%
Revenue growth 3Y17.43%
Revenue growth 5YN/A
Sales Q2Q%46.6%

3.2 Future

Based on estimates for the next years, EXAI will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.83% on average per year.
EXAI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.58% yearly.
EPS Next Y42.38%
EPS Next 2Y17.98%
EPS Next 3Y19.83%
EPS Next 5YN/A
Revenue Next Year63.9%
Revenue Next 2Y8.4%
Revenue Next 3Y13.58%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXAI Yearly Revenue VS EstimatesEXAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
EXAI Yearly EPS VS EstimatesEXAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EXAI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EXAI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EXAI Price Earnings VS Forward Price EarningsEXAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EXAI Per share dataEXAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

EXAI's earnings are expected to grow with 19.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.98%
EPS Next 3Y19.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EXAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXSCIENTIA PLC

NASDAQ:EXAI (11/19/2024, 8:18:05 PM)

After market: 4.85 +0.01 (+0.21%)

4.84

+0.15 (+3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)N/A N/A
Inst Owners20.13%
Inst Owner Change-0.04%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap633.18M
Analysts47.5
Price Target5.46 (12.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-94.46%
Min EPS beat(2)-216.45%
Max EPS beat(2)27.53%
EPS beat(4)2
Avg EPS beat(4)-45.8%
Min EPS beat(4)-216.45%
Max EPS beat(4)27.53%
EPS beat(8)4
Avg EPS beat(8)-21.41%
EPS beat(12)5
Avg EPS beat(12)-64.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-29.54%
Min Revenue beat(2)-57.12%
Max Revenue beat(2)-1.96%
Revenue beat(4)1
Avg Revenue beat(4)-7.8%
Min Revenue beat(4)-81.79%
Max Revenue beat(4)109.67%
Revenue beat(8)1
Avg Revenue beat(8)-18.19%
Revenue beat(12)3
Avg Revenue beat(12)23.22%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.83%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.73
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.85
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.2
BVpS3.45
TBVpS3.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.37%
ROE -36.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.33%
ROA(5y)-19.31%
ROE(3y)-25.04%
ROE(5y)-27.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.01%
Cap/Sales 35.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.22
Quick Ratio 6.22
Altman-Z 1.78
F-Score4
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)192.5%
Cap/Depr(5y)219.19%
Cap/Sales(3y)80.38%
Cap/Sales(5y)56.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-24.14%
EPS Next Y42.38%
EPS Next 2Y17.98%
EPS Next 3Y19.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.64%
Revenue growth 3Y17.43%
Revenue growth 5YN/A
Sales Q2Q%46.6%
Revenue Next Year63.9%
Revenue Next 2Y8.4%
Revenue Next 3Y13.58%
Revenue Next 5YN/A
EBIT growth 1Y32.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.36%
EBIT Next 3Y15.52%
EBIT Next 5YN/A
FCF growth 1Y-289.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-251.15%
OCF growth 3YN/A
OCF growth 5YN/A